Cellebrite DI (CLBT)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $2.90B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cellebrite DI (CLBT) P/E Ratio & Valuation History
Cellebrite DI (CLBT) trades at 25.3x trailing earnings and 5.3x sales. Its P/E of 25.3x is below its 5-year median of 31.2x. Its forward P/E is 35.7x. The median P/E across 12 similar companies is 27.0x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 29.1% lower over the next year. Its free cash flow yield is 5.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 25.3x |
| Forward P/E | 35.7x |
| Price to sales | 5.3x |
| Price to book | 4.9x |
| Price to FCF | 17.5x |
| PEG | N/A |
| FCF yield | 5.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 25.3x | 31.2x | N/A |
| P/S | 5.3x | 6.0x | N/A |
Valuation History
Over the 5 year ends shown, its P/E ranged from 16.1x in 2022 to 52.5x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $18.03 | 36.1x | 9.5x | 9.4x |
| 2024 | $22.03 | 52.5x | 11.7x | 16.2x |
| 2023 | $8.66 | 29.9x | 5.2x | 49.2x |
| 2022 | $4.36 | 16.1x | 3.1x | 11.4x |
| 2021 | $8.02 | 21.1x | 6.0x | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CLBT
What is CLBT's forward P/E ratio?
Cellebrite DI has a forward P/E ratio of 35.7x.
Is CLBT stock overvalued?
GNG's valuation label for CLBT is Undervalued. Its P/E of 25.3x compares with a median of 27.0x across 12 similar companies.
What is CLBT's price to sales ratio?
Cellebrite DI has a price to sales ratio of 5.3x.
What is Cellebrite DI's average P/E ratio over 5 years?
Cellebrite DI's median P/E over the last 5 years is 31.2x, from 60 month-end values through Oct 2026.
CLBT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts